Blood of an American man who deliberately injected himself with snake venom nearly 200 times has led to an "unparalleled" antivenom. Scientists have said that antibodies found in Tim Friede's blood have been shown to protect against fatal doses of venom from a wide variety of snakes, including kraits and cobras. It could be a breakthrough in treatment against snakebites, as all current therapies against snakebites have to match the specific species of venomous snake that anyone has been bitten by.

How Dangerous Is A Snakebite?

Someone dies from a snakebite every 4 to 6 minutes, according to the World Health Organisation (WHO). The highest mortality rates occur in South Asia, sub-Saharan Africa, and Southeast Asia, where access to medical care and antivenoms is often limited. India alone accounts for nearly half of all snakebite deaths globally, with rural populations being the most vulnerable. Beyond fatalities, snake bites can cause severe disabilities, including amputations and chronic pain. Many survivors suffer long-term psychological trauma and socioeconomic setbacks due to prolonged recovery and loss of livelihood. WHO also revealed that over a third of snakebite victims are under the age of 20, highlighting the significant risk faced by younger populations in tropical regions, particularly in Asia, Africa, and Latin America.

The effects of snake venom can be devastating, leading to various complications and sometimes permanent disabilities. Shockingly, for every person who succumbs to a snakebite, three others may survive but live with lasting physical impairments, resulting in a continuous loss of income for families, especially if the victim is the primary breadwinner.

How To Prevent Snakebites

Prevention is key when it comes to snakebites, especially for those living or working in snake-prone areas. Here are some practical steps to reduce the risk:

1. Be Cautious: Be mindful of where you place your hands and feet. Avoid reaching into unknown spaces or under objects without checking for hidden snakes.

2. Stay Aware: Keep an eye on your surroundings. Avoid lying down or sitting in areas that might harbour snakes.

3. Dress Appropriately: Wear high-top boots and long pants when navigating through dense vegetation to provide better protection against snake bites.

4. Avoid Handling Snakes: Do not attempt to capture, handle, or keep snakes, as this increases your risk of being bitten.

5. Back Away Slowly: If you encounter a snake, calmly back away and do not attempt to touch or provoke it.

How Are Traditional Antivenoms Created?

The process of creating antivenoms typically involves immunising animals like horses or sheep with venom from a single species of snake. These animals then produce antibodies that are harvested and used to treat envenomated patients. While this is an effective treatment, the method has some limitations. It includes the possibility of adverse reactions to non-human antibodies. The fact that treatments tend to be species-specific it could then mean that if a person is bitten by one type of snake, then it may not benefit from an antivenom developed from a different species.

Nicotine pouches have become popular in the UK, show many studies, this is especially true in the case of young adults.

In fact, a new study done by the researches from University College London (UCL) has found that in the last five years, there has been an increase from 0.1 per cent to 1 per cent of adults using nicotine pouches. This means, around 522,000 more people in the UK have started using the pouches.

How Does A Nicotine Pouch Work?

The pouches are placed between the lip and gum and it releases nicotine slowly. The pouches are also available in variety of flavors, with sweeteners and plant-based fibers. It does not contain tobacco like vapes do and usually are considered to be a healthier alternative to smoking.

Health and Me ran a fact check on whether it truly is safer than smoking, and here is what we found.

Are Nicotine Pouches Safer Than Smoking?

"This risks are substantially less than some other nicotine products like smoking, because there is no tobacco and there is no combustion," said Dr Harry Tattan-Birch, the lead author of the study, to Mornings with Ridge and Frost.

"And we know the combustion of tobacco is the thing that causes most of the diseases related to smoking," he says.

However, he and his team has warned that while it may not cause serious illness like tobacco can, young people could have a negative impact in their lungs and brains, as they are still in developing stage. This makes them more sensitive to the effects of nicotine, and it could become difficult to stop using it.

A UCL research fellow earlier told Sky News that while nicotine pouches are far less harmful than smoking, their long-term effects remain unclear because they are relatively new. Drawing on what is known about their contents, she noted they are not risk-free, as users are still exposed to some toxic substances, albeit at much lower levels.

Who Are Using These Nicotine Pouches?

Researchers from UCL, supported by Cancer Research UK, analysed survey responses from 127,793 people aged 16 and above across England, Scotland and Wales, collected between October 2020 and March 2025.

Their analysis showed that nicotine pouch use among 16 to 24-year-olds rose to 4% in 2025, up from just 0.7% in 2022. The increase was most pronounced among young men, with one in 13 men in this age group, or 7.5%, reporting use.

Overall, men accounted for 72% of nicotine pouch users between 2022 and 2025, while 47% were under the age of 25. Dr Tattan-Birch said the growth in use has been driven almost entirely by young people, particularly young men, with usage among adults over 35 remaining low and largely unchanged.

He added that this trend also includes children. Since nicotine pouches are not classified as tobacco or vape products, there are currently no age limits. Advertising is also unrestricted, allowing brightly coloured, sweet-flavoured products to appeal to younger audiences.

Do Nicotine Pouches Help Quit Smoking?

The research found that 69 per cent of pouch users were reported using other nicotine products, while 56 per cent of them smoked, as per the survey from January 2022 to March 2025.

1 in 6, which makes it 16 per cent said they never regularly smoked. "Whether nicotine pouches are good or bad for public health depends on who is using them. If it's a young person who would otherwise start smoking, then the use of pouches might help to reduce harm. However, if it's a person who otherwise would not use nicotine at all, then the potential for harm increases," said Tattan-Birch.

A woman experiencing abdominal discomfort went to her gynecologist for an ultrasound, only to discover something far more startling than a baby. The mom, who shares her story on TikTok under the handle @sandwitchbread, revealed her medical surprise in a video that has now amassed over 1.9 million views. She said she had been struggling with pain and unusual bleeding since giving birth to her two-year-old son and decided to see a gynecologist fearing she might be pregnant again.

During the ultrasound, she noticed something on the screen, but the doctor quickly reassured her it wasn’t a baby. “When my doctor came in to share the results,” the TikToker recalled, “she looked me in the eyes and told me I had a seven-centimeter cyst, about the size of a chicken egg, called a dermoid cyst.”

What Is A Dermoid Cyst?

A dermoid cyst is a pocket of tissue growth that can contain normal body tissues, sometimes including hair, fluid, teeth, or skin. While this TikToker’s cyst was in her uterus, dermoid cysts are most commonly found in the ovaries. They are generally harmless but often require surgical removal. According to the National Cancer Institute, dermoid cysts are present from birth but may not be detected until later in life. These benign tumors originate from embryonic cells that become “trapped” and develop into tissues in the wrong location. Teeth and hair are frequent components, and surgery is usually recommended if the cyst causes symptoms or complications.

Why Do Dermoid Cysts Have Hair and Teeth?

Dermoid cysts develop hair and teeth because they arise from trapped embryonic cells (ectoderm) that can grow into skin, hair follicles, sweat glands, and even teeth, instead of forming the tissues normally found in the ovary or skin. Essentially, they are benign tumors made up of mature but misplaced body tissues from the outer layer of the embryo, which normally forms skin and related structures.

Dermoid Cysts: Symptoms

Most ovarian dermoid cysts remain symptom-free unless complications occur. When symptoms do appear, the most common one reported is lower abdominal pain.

As the cyst enlarges, it can cause noticeable abdominal swelling and problems with the urinary or digestive system.

In more severe cases, individuals might also experience:

• Fever
• Intense abdominal pain
• Unusual vaginal bleeding
• Unexplained weight loss

The Office on Women’s Health notes that cysts on the ovaries can also cause:

• Pressure in the abdomen
• Bloating
• Abdominal swelling
• Pain in the lower abdomen

Dermoid Cysts: Possible Complications

Some potential complications include:

Rupturing of the cyst: Though rare, ovarian dermoid cysts can burst. If the cyst’s contents leak into the abdominal cavity, it may lead to chronic inflammation of the abdominal lining (peritonitis). In some cases, leakage into the intestines or rectum can result in the material being expelled through the anus.

Ovarian torsion: This occurs when the cyst twists the ligaments holding the ovary in place, which can cut off blood supply to the ovary and fallopian tube.

Infection: The risk of infection is around 1–4%. Severe infections may lead to cyst rupture.

Malignant transformation: Dermoid cysts are almost always benign, but in rare instances, they can become cancerous.

A new weight-loss drug often described as the “triple G” treatment because it mimics three hormones linked to hunger and metabolism has delivered striking results in fresh data shared Thursday by its developer, Eli Lilly. In a clinical study involving more than 400 people living with obesity and knee osteoarthritis, the experimental drug retatrutide led to an average weight reduction of 71 pounds, or close to 29% of total body weight, over a period of 16 months, according to figures released by the company. Participants who received retatrutide also reported a 76% drop in knee pain by the end of the study period, based on the same data. So is

What Is Retatrutide?

Retatrutide is an experimental weight-loss drug developed by Eli Lilly and is widely seen as a next-step advancement beyond current GLP-1-based medications such as semaglutide and tirzepatide. While semaglutide acts on a single hormone pathway and tirzepatide works on two, retatrutide targets three.

It activates GLP-1 and GIP, along with an added glucagon pathway, which is why it is sometimes informally referred to as a “GLP-3” drug. Researchers believe this third pathway could explain the greater weight-loss effects seen so far, although retatrutide remains under investigation and has not yet received FDA approval.

Why Is Retatrutide Trending?

Even without regulatory approval, retatrutide has gained attention among gym enthusiasts, fitness creators, and online weight-loss communities. On platforms like TikTok, where direct searches for #reta or #retatrutide are restricted, users often refer to it using coded terms such as “ratatouille.”

At the same time, the drug has been in the news due to growing concerns about counterfeit versions. Reports from the UK recently revealed that authorities seized more than £250,000 worth of fake weight-loss injection pens labelled as tirzepatide and retatrutide from a hidden factory in Northampton. These products are especially concerning because retatrutide is still in clinical trials and has not been approved for use anywhere in the world.

How Is Retatrutide Different Than Other Weight-Loss Drugs?

Retatrutide works by mimicking three hormones that play a role in appetite and metabolism: GLP-1, GIP, and glucagon. In contrast, most weight-loss drugs currently available target only one or two of these pathways. Ozempic and Wegovy, made by Novo Nordisk, copy the effects of GLP-1, a hormone that influences the brain, pancreas, stomach, liver, and muscles, according to the National Institutes of Health.

Mounjaro and Zepbound, on the other hand, act on both GLP-1 and GIP, a hormone involved in blood sugar regulation through insulin stimulation. Retatrutide’s added glucagon effect is key, as glucagon is known to support fat burning, even when the body is at rest. Ozempic and Mounjaro are approved by the FDA for treating Type 2 diabetes, while Wegovy and Zepbound are approved for people with overweight or obesity. As with any prescription drug, it is important for individuals to consult a healthcare professional to determine whether these treatments are appropriate for them.

When Is Retatrutide Expected To Be Available To Consumers?

There is currently no confirmed timeline for when retatrutide might become available by prescription. Its launch will depend on the FDA’s detailed evaluation of clinical trial data once it is formally submitted. Based on current expectations, approval is unlikely before late 2026 and could potentially extend into 2027 or even 2028.